Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by grosdavidon Apr 26, 2020 12:20pm
163 Views
Post# 30954812

RE:Algernon treatment

RE:Algernon treatmentNP-120 has been recognized mostly in Asia, South Korea mainly because of the Bird Flu attacked mostly that part of the Earth. Not too many cases in America that is why they want a certain assurance.

When you read the NR, you understand that HC and FDA are asking for a MINIMUM of proven data, they are not asking the full Pre-Clinicals trials, Phase 1, ETC...

I share the same opinion. But it is what it is. Go read the about the similarities of the Bird Flu and the Covid19, similar symptoms. 

They have to take this case seriously, they can't skip a step which could have such an impact on the lives millions of people. I understand the frustration, many of us share the same view.

There is no incompetence here, AGN has done everything right in my opinion, they have to adjust and respond to different Gov. bodies that require different measures.

Undervalued, huge potential. There is risk, like with any company.

Good news that two treatments failed last week. This week will bring more and more exposure.

David
Bullboard Posts